Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection

Journal of Infectious Diseases

Volumn 213, Issue 7, 2016, Pages 1124-1133

  Dowall, Stuart David ^a   Callan, Jo ^b   Zeltina, Antra ^c   Al Abdulla, Ibrahim ^b   Strecker, Thomas ^d   Fehling, Sarah K ^d   Krähling, Verena ^d   Bosworth, Andrew ^a   Rayner, Emma ^a   Taylor, Irene ^a   Charlton, Sue ^a   Landon, John ^b   Cameron, Ian ^b   Hewson, Roger ^a   Nasidi, Abdulsalami ^e   Bowden, Thomas A ^c   Carroll, Miles W ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Newcastle Emlyn   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e NIGERIA CENTRE FOR DISEASE CONTROL   (Nigeria)

Author keywords

Antibody; Ebola; Efficacy; Neutralization; Therapeutic

Indexed keywords

EBOTAB; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; GLYCOPROTEIN; MEMBRANE PROTEIN; PROTEIN BINDING; VIRUS ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD; ANIMAL; COST BENEFIT ANALYSIS; ECONOMICS; GENE EXPRESSION REGULATION; GUINEA PIG; HEK293 CELL LINE; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SHEEP;

ANIMALS; ANTIBODIES, VIRAL; COST-BENEFIT ANALYSIS; EBOLAVIRUS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GLYCOPROTEINS; GUINEA PIGS; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; MEMBRANE GLYCOPROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SHEEP; VIRAL LOAD;

EID: 84962549897     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv565     Document Type: Article

References (35)

1. Adams MJ, Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2012). Arch Virol 2012; 157:1411-22.
2. Kuhn JH, Becker S, Ebihara H, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010; 155:2083-103.
3. Baize S, Pannetier D, Oesterreich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371:1418-25.
4. Kupferschmidt K, Cohen J. Infectious diseases. Ebola drug trials lurch ahead. Science 2015; 347:701-2.
5. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.
6. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(suppl 1):S18-23.
7. van Griensven J, De Weiggheleire A, Delamou A, et al. The use of Ebola Convalescent Plasma to treat Ebola Virus Disease in resource-constrained settings: a perspective from the field. Clin Infect Dis 2015; doi:10.1093/cid/civ680.
8. Gulland A. First Ebola treatment is approved by WHO. BMJ 2014; 349:g5539.
9. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 2014; 345:1369-72.
10. Murin CD, Fusco ML, Bornholdt ZA, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A 2014; 111:17182-7.
11. Kreil TR. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg Infect Dis 2015; 21:521-3.
12. Redwan el RM, Fahmy A, El Hanafy A, Abd El-Baky N, Sallam SM. Ovine antirabies antibody production and evaluation. Comp Immunol Microbiol Infect Dis 2009; 32:9-19.
13. Redwan el RM, Khalil A, El-Dardiri ZZ. Production and purification of ovine antitetanus antibody. Comp Immunol Microbiol Infect Dis 2005; 28:167-76.
14. Chippaux JP, Boyer LV, Alagon A. Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy. J Venom Anim Toxins Incl Trop Dis 2015; 21:3.
15. Habib AG. Public health aspects of snakebite care in West Africa: perspectives from Nigeria. J Venom Anim Toxins Incl Trop Dis 2013; 19:27.
16. Aricescu AR, LuW, Jones EY. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr 2006; 62 (Pt 10):1243-50.
17. Curd J, Smith TW, Jaton J-C, Haber E. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proc Natl Acad Sci U S A 1971; 68:2401-6.
18. Casewell NR, Cook DA, Wagstaff SC, et al. Pre-clinical assays predict pan-African Echis viper efficacy for a species-specific antivenom. PLoS Negl Trop Dis 2010; 4: e851.
19. Trombley AR, Wachter L, Garrison J, et al. Comprehensive panel of real-time Taq- Man polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and NewWorld hantaviruses. Am J Trop Med Hyg 2010; 82:954-60.
20. Dowall S, Taylor I, Yeates P, et al. Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody. Antiviral Res 2013; 97:108-11.
21. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008; 454:177-82.
22. Stevens NE, Fraser CK, Alsharifi M, Brown MP, Diener KR, Hayball JD. An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT is functionally superior to Freund's adjuvant. PLoS One 2013; 8:e68895.
23. Al-Abdulla I, Casewell NR, Landon J. Long-term physicochemical and immunological stability of a liquid formulated intact ovine immunoglobulin-based antivenom. Toxicon 2013; 64:38-42.
24. Mohan GS, Li W, Ye L, Compans RW, Yang C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 2012; 8: e1003065.
25. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE. Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog 2014; 10:e1004509.
26. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. N Engl J Med 2015; doi:10.1056/NEJMoa1502924.
27. Kuhn JH, Lofts LL, Kugelman JR, et al. Reidentification of Ebola Virus E718 and ME as Ebola Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran. Genome Announc 2014; 2:e01178-14.
28. Pernet O, Schneider BS, Beaty SM, et al. Evidence for henipavirus spillover into human populations in Africa. Nat Commun 2014; 5:5342.
29. Kugelman JR, Sanchez-Lockhart M, Andersen KG, et al. Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics. MBio 2015; 6:e02227-14.
30. Audet J, Wong G, Han W, et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep 2014; 4:6881.
31. Kudoyarova-Zubavichene NM, Sergeev NN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis 1999; 179(suppl 1):S218-23.
32. Kaur M, Garg R, Singh S, Bhatnagar R. Rabies vaccines: where do we stand, where are we heading? Expert Rev Vaccines 2015; 14:369-81.
33. Qiu X, Wong G, Fernando L, et al. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013; 5:207ra143.
34. Bolton FM, Casewell NR, Al-Abdulla I, Landon J. Production and assessment of ovine antisera for the manufacture of a veterinary adder antivenom. Vet Rec 2014; 174:406.
35. Smith DC, Reddi KR, Laing G, Theakston RG, Landon J. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon 1992; 30: 865-71.